Alzheimer’s News Today

3 days ago | alzheimersnewstoday.com | Lindsey Shapiro

Leqembi (lecanemab) has won marketing authorization in the European Union for the treatment of certain adults with early Alzheimer’s disease, making it the first therapy that targets an underlying cause of the neurodegenerative condition to be approved in the region. The treatment is indicated for adults with mild cognitive impairment or mild dementia due to Alzheimer’s who have confirmed buildup in the brain of the amyloid-beta protein — the disease hallmark that Leqembi targets.

2 weeks ago | alzheimersnewstoday.com | Margarida Maia

Cassava Sciences will discontinue developing simufilam for mild to moderate Alzheimer’s disease by the end of the second quarter of this year after the experimental treatment failed to meet key Phase 3 trial goals for improving cognition and daily function.

1 month ago | alzheimersnewstoday.com | Lindsey Shapiro |Ray Burow |Mary Chapman |Patricia Inacio

Age at menopause may interact with factors related to the health of synapses, or nerve cell connections, to influence the risk of Alzheimer’s disease in women, a study found. Associations between biomarkers of poor synapse health and higher levels of Alzheimer’s-related proteins in the brain, as well as steeper cognitive declines, were stronger when menopause was experienced at a younger age, the researchers said.

2 months ago | alzheimersnewstoday.com | Andrea Lobo |Ray Burow |Margarida Maia |Lindsey Shapiro

The U.S. Food and Drug Administration (FDA) has approved monthly maintenance dosing for Leqembi (lecanemab), a treatment for early Alzheimer’s disease. The decision follows a supplemental application from Eisai, which is codeveloping Leqembi with Biogen, based on the modeling of data from the Phase 2 Study 201 (NCT01767311) and the Phase 3 Clarity AD study (NCT03887455), and their long-term extension studies, showing that once-monthly dosing can help sustain the therapy’s beneficial effects.

2 months ago | alzheimersnewstoday.com | Ray Burow |Marisa Wexler

“I’ve never been so cold in my life.”I recently visited Washington, D.C., and it was cold — perhaps not by the standards of northern states, but bitter compared with my home in South Florida. Now, I’ve been colder in my life, but the quotation above pumped through my mind while I was there, prompting a warm memory of my mother. She said those words early in her dementia journey and my caregiving adventure when, a year or so after my father’s passing, his only brother passed away, too.